use based on serovar determination, and assess rodent, livestock, and wildlife reservoirs of leptospirosis based on infecting serovars found in dogs. Findings from this study will aid in the development of evidence-based, targeted interventions for the prevention of canine leptospirosis, be used to focus human leptospirosis surveillance efforts, and guide future investigations on leptospirosis in humans and animals in Puerto Rico.

The information collection for which approval is sought is in accordance with BSPB’s mission to prevent illness, disability, or death caused by bacterial zoonotic diseases through surveillance, epidemic investigations, epidemiologic and laboratory research, training and public education. Authorizing Legislation comes from Section 301 of the Public Health Service Act (42 U.S.C. 241). Successful execution of BSPB’s public health mission requires data collection activities in collaboration with the state health department in Puerto Rico and with local veterinary clinics and animal shelters participating in the study.

These activities include collecting information about dogs that meet the study case definition for a suspect case of leptospirosis seen at participating veterinary clinics and shelters. The information is collected by veterinarians or their veterinary technical staff by interviewing the dog owner and reviewing medical and administrative records, as necessary. Basic information about the participating sites will also be collected for study management, as well as to augment data analysis.

Approval of this data collection tool will allow BSPB to collect information from veterinarians, vet staff and dog owners about the dog’s signalment, risk factors, clinical signs and symptoms, laboratory results, treatment, and outcome. The study will also collect basic site information from participating clinics and shelters, including information about site capacity, vaccination practices, origin of dogs, and resources available at the sites.

Data collection tools will be completed onsite. For dogs that have an owner, information about the dog may be collected by veterinarians and their vet staff by interviewing the dog owner. Otherwise, data collection tools may be completed by reviewing administrative and medical records, as necessary. Data will be recorded on paper forms. Study coordinators will enter collected data into an electronic database.

BSPB estimates involvement of at least 411 respondents (385 from the general public and 26 veterinarians and their veterinary technical staff) and estimates a total of 168 hours of burden for research activities each year. The collected information will not impose a cost burden on the respondents beyond that associated with their time to provide the required data.

---

**Estimated Annualized Burden Hours**

<table>
<thead>
<tr>
<th>Type of respondents</th>
<th>Form name</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average burden per response (in hours)</th>
<th>Total burden (in hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Veterans or vet technical staff ...</td>
<td>Enrollment Questionnaire</td>
<td>26</td>
<td>1</td>
<td>5/60</td>
<td>2</td>
</tr>
<tr>
<td>Veterans or vet technical staff ...</td>
<td>Log Sheet</td>
<td>26</td>
<td>24</td>
<td>1/60</td>
<td>10</td>
</tr>
<tr>
<td>Veterans or vet technical staff ...</td>
<td>Case Questionnaire</td>
<td>26</td>
<td>24</td>
<td>15/60</td>
<td>156</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>168</td>
</tr>
</tbody>
</table>

**Place:** CDC, 1600 Clifton Road NE., Tom Harkin Global Communications Center, Building 19, Auditorium B, Atlanta, Georgia 30329.

**Status:** Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people. This meeting will also be webcast, please see information below.

**Purpose:** This Committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services (HHS); the Assistant Secretary for Health; the Director, Centers for Disease Control and Prevention; the Commissioner, Food and Drug Administration (FDA); and the Administrator, Centers for Medicare and Medicaid Services (CMS). The advice and guidance pertain to general issues related to improvement in clinical laboratory quality and laboratory medicine practice and specific questions related to possible revision of the Clinical Laboratory Improvement Amendment (CLIA) standards. Examples include providing guidance on studies designed to improve safety, effectiveness, efficiency, timeliness, equity, and patient-centeredness of laboratory services; revisions to the standards under which clinical laboratories are regulated; the impact of proposed revisions to the standards on medical and laboratory practice; and the modification of the standards and provision of non-regulatory guidelines to accommodate technological advances, such as new test methods, the electronic transmission of laboratory information, and mechanisms to improve the integration of public health and clinical laboratory practices.

**Matters for Discussion:** The agenda will include agency updates from CDC, CMS, and FDA. Presentations and discussions will include a report on the cytology workload assessment and time measure study; an update on CLIA recommendations for laboratory biosafety; laboratory preparedness and response: The case of Zika; a report from the Institute of Medicine (IOM) CLIA workgroup; and future CLIA topics. Agenda items are subject to change as priorities dictate.

**Webcast:** The meeting will also be webcast. Persons interested in viewing
the webcast can access information at: http://
cdclabtraining.adobeconnect.com/
novembercliac/.

Online Registration Required: All people attending the CLIAC meeting in
person are required to register for the
meeting online at least 5 business days
in advance for U.S. citizens and at least
10 business days in advance for
international registrants. Register at:
http://wwwn.cdc.gov/cliac/Meetings/
MeetingDetails.aspx. Register by
scrolling down and clicking the
“Register for this Meeting” button and
completing all forms according to the
instructions given. Please complete all
the required fields before submitting
your registration and submit no later
than October 27, 2016 for U.S.
registrants and October 20, 2016 for
international registrants.

Providing Oral or Written Comments:
It is the policy of CLIAC to accept
written public comments and provide a
brief period for oral public comments on
agenda items. Public comment periods
for each agenda item are scheduled
immediately prior to the Committee
discussion period for that item.

Oral Comments: In general, each
individual or group requesting to make
oral comments will be limited to a total
time of five minutes (unless otherwise
indicated). Speakers must also submit
their comments in writing for inclusion in
the meeting’s Summary Report. To
assure adequate time is scheduled for
public comments, speakers should
notify the contact person below at least
one week prior to the meeting date.

Written Comments: For individuals or
groups unable to attend the meeting,
CLIAC accepts written comments until
the date of the meeting (unless
otherwise stated). However, it is
requested that comments be submitted
at least one week prior to the meeting
date so that the comments may be made
available to the Committee for their
consideration and public distribution.
Written comments, one hard copy with
original signature, should be provided
to the contact person at the mailing or
email address below, and will be
included in the meeting’s Summary
Report.

Availability of Meeting Materials: To
support the green initiatives of the
federal government, the CLIAC meeting
materials will be made available to the
Committee and the public in electronic
format (PDF) on the internet instead of
by printed copy. Check the CLIAC Web
site on the day of the meeting for
materials: http://wwwn.cdc.gov/cliac/
MeetingDetails.aspx. Note: If
using a mobile device to access the
materials, please verify that the device’s
browser is able to download the files
from the CDC’s Web site before the
meeting.

Alternatively, the files can be
downloaded to a computer and then
e-mailed to the portable device. An
internet connection, power source, and
limited hard copies may be available at
the meeting location, but cannot be
guaranteed.

Contact Person for Additional
Information: Nancy Anderson, Chief,
Laboratory Practice Standards Branch,
Division of Laboratory Systems, Center
for Surveilliance, Epidemiology and
Laboratory Services, Office of Public
Health Scientific Services, Centers for
Disease Control and Prevention, 1600
Clifton Road NE., Mailstop F–11,
Atlanta, Georgia 30329; telephone (404)
498–2741; or via email at
NAnderson@
cdc.gov.

The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for Centers for
Disease Control and Prevention and the
Agency for Toxic Substances and Disease
Registry.

Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.

[FR Doc. 2016–24785 Filed 10–12–16; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

National Institutes of Health

Office of the Director, National
Institutes of Health; Notice of Closed
Meeting

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.

The meeting will be closed to
the public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

Name of Committee: Scientific and
Technical Review Board on Biomedical and
Behavioral Research Facilities.

Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).

Contact Person: Ross D. Shonat, Ph.D.,
Scientific Review Officer, Center for